Keyphrases
Fosaprepitant
37%
Aprepitant
37%
Anti-PD-1 Antibody
37%
Pharmaceutical Consultation
37%
Immune Checkpoint Inhibitors
37%
Cancer-associated Thrombosis
37%
L-OHP
37%
Cancer Patients
37%
Small Breast Carcinoma
37%
Quality of Returns
37%
Work Rate
37%
Japan
37%
Colorectal Cancer Stem Cells
37%
Multidisciplinary Management
37%
Return to Work
37%
Trastuzumab Deruxtecan (T-DXd)
37%
Methodological Quality
37%
Postmastectomy
37%
S100A10
37%
MFOLFOX6
26%
Extrapulmonary Small Cell Carcinoma
18%
TCR-T Therapy
18%
Primary Small Cell Carcinoma
18%
Modified Radical Mastectomy
18%
Thrombocytopaenia
15%
High Risk
14%
Selection Bias
14%
Forming Capacity
14%
Delayed Vomiting
12%
Cancer of Unknown Primary
12%
Pleural Thymoma
10%
Reporting Bias
9%
Cancer Diagnosis
9%
Self-management
9%
Anti-cancer Drug Treatment
9%
Employment Status
9%
Attrition Bias
9%
Dynamic Matrix
7%
Matrix Rearrangement
7%
Fibronectin Matrix
7%
Matrix Influence
7%
Fluoropyrimidine Therapy
7%
Breast Cancer Survivors
7%
Dose Individualization
7%
High-dose Chemotherapy
6%
Acute Nausea
6%
Complete Control
6%
Questionnaire Form
6%
Hemoglobin Count
6%
Chemotherapy Dose
6%
Tipiracil
6%
Trifluridine
6%
Nivolumab
5%
Arterial Thromboembolism
5%
High Safety
5%
Platinum-based Agents
5%
Unresectable Rectal Cancer
5%
Unresectable Colon Cancer
5%
Injection Timing
5%
Reaction Rate
5%
Radiation Dermatitis
5%
Chest Wall Irradiation
5%
Metastasis Promoter
5%
Breast CSCs
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Malignant Neoplasm
86%
Immune Checkpoint Inhibitor
54%
Chemotherapy
40%
Non Small Cell Lung Cancer
37%
Erlotinib
37%
Meglumine
37%
Aprepitant
37%
Cancer Chemotherapy
37%
Fosaprepitant
37%
Liver Dysfunction
37%
Cohort Study
37%
Colorectal Cancer
37%
Prevalence
37%
Small Cell Carcinoma
37%
microRNA 221
37%
Blood Toxicity
37%
Allergic Reaction
37%
Bilirubin
37%
Etoposide
24%
Skin Disease
12%
Recurrent Disease
12%
Cisplatin
12%
Disease
12%
Small Cell Lung Cancer
12%
Distant Metastasis
12%
Neoplasm
12%
Cyclophosphamide
12%
Epirubicin
12%
Cancer of Unknown Primary Site
12%
Epileptic Absence
11%
Thymoma
10%
Anticarcinogen
9%
Pharmacotherapy
9%
Breast Cancer
8%
Nivolumab
7%
Colon Cancer
5%
Dexamethasone
5%
Monotherapy
5%
Combination Therapy
5%
Arterial Thromboembolism
5%
Venous Thromboembolism
5%
Radiation Dermatitis
5%
Medicine and Dentistry
Breast Cancer
46%
Cancer Stem Cell
37%
Fibronectin
37%
Upregulation
37%
Cytoskeleton
37%
Malignant Neoplasm
37%
Adipogenesis
37%
Integrin
37%
Pemetrexed
37%
microRNA 221
37%
Immune Checkpoint Inhibitor
37%
Prevalence
37%
Blood Toxicity
37%
Actin
37%
Trastuzumab Deruxtecan
37%
Adipocyte
32%
Cancer Cell
24%
Tumor Xenograft
18%
Modified Radical Mastectomy
18%
Epirubicin
18%
Metastatic Carcinoma
18%
Extracellular Matrix
15%
Cancer of Unknown Primary Origin
12%
Leukemia
10%
Downregulation
10%
Cell Differentiation
10%
Promoter Region
6%
Organoid
6%
In Vitro
6%
Hospital Anxiety and Depression Scale
6%
Matrix Metalloproteinase
6%
Cell Marker
6%
Protein Family
6%
Population
6%
Venous Thromboembolism
5%
Nivolumab
5%
Arterial Thromboembolism
5%
Receptor
5%
Treatment of Non-Small Cell Lung Cancer
5%
Colorectal Carcinoma Cell Line
5%
Cell Surface
5%
Peroxisome
5%